BioCentury | Jan 3, 2020
Emerging Company Profile

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

Click is developing a pipeline of personalized prescription digital therapeutics that could be used alone or in combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. Launched in 2012, Click Therapeutics Inc. markets a...
BC Week In Review | Mar 14, 2019
Company News

Akili creates global access platform for digital therapeutics, grants Shionogi license

Shionogi gained exclusive rights to develop and commercialize Akili's digital therapeutics for ADHD and autism spectrum disorder (ASD) in Japan and Taiwan. Akili Interactive Labs Inc. (Boston, Mass.) will receive $20 million up front and...
Items per page:
1 - 2 of 2